Related Experiment Videos
Selegiline for Parkinson's disease.
1Hahnemann University School of Medicine, Philadelphia, Pennsylvania.
American Family Physician
|February 1, 1990
Summary
Selegiline, a selective monoamine oxidase inhibitor, effectively manages Parkinson's disease symptoms when combined with carbidopa/levodopa. This combination allows for reduced carbidopa/levodopa dosage, diminishing side effects and improving patient outcomes.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Medicine
Background:
- Nonselective monoamine oxidase inhibitors (MAOIs) affect both brain and peripheral MAO.
- Parkinson's disease management has historically relied on nonselective MAOIs.
Purpose of the Study:
- To evaluate the efficacy and safety of selegiline, a selective MAOI, in Parkinson's disease management.
- To assess the benefits of combining selegiline with carbidopa/levodopa.
Main Methods:
- Clinical trials were conducted to assess selegiline's effectiveness.
- Patient outcomes were monitored when selegiline was added to carbidopa/levodopa therapy.
Main Results:
- Selegiline in combination with carbidopa/levodopa effectively relieved Parkinson's disease symptoms.
- The combination therapy prolonged remission periods.
- Dosage reduction of carbidopa/levodopa was often possible, leading to fewer side effects.
- Selegiline demonstrated a relatively nontoxic profile.
Conclusions:
- Selegiline is a valuable therapeutic addition for Parkinson's disease.
- Selective MAOIs like selegiline offer an improved treatment option for Parkinson's disease patients.
- Combining selegiline with carbidopa/levodopa enhances symptom control and tolerability.